Looking for a new broker?
Biomea Fusion, Inc. stock is up 98.24% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 05 Dec 15:38 | 19 Jan, 2024 | 25.00 | 505 | ||
| 05 Dec 16:28 | 19 Jan, 2024 | 35.00 | 3194 | ||
| 05 Dec 20:06 | 19 Jan, 2024 | 10.00 | 1729 | ||
| 05 Dec 20:12 | 19 Apr, 2024 | 35.00 | 197 | ||
| 05 Dec 20:18 | 19 Apr, 2024 | 35.00 | 197 | ||
| 05 Dec 20:18 | 19 Apr, 2024 | 35.00 | 197 | ||
| 07 Dec 16:01 | 19 Jan, 2024 | 20.00 | 54 | ||
| 07 Dec 20:47 | 19 Jan, 2024 | 10.00 | 2155 | ||
| 08 Dec 20:29 | 15 Dec, 2023 | 22.50 | 4254 | ||
| 08 Dec 20:29 | 15 Dec, 2023 | 22.50 | 4254 |
Biomea Fusion, Inc. focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
